SEARCH:   Advanced

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Cohen, H. J. Articles by Bartolucci, A. A. Search for Related Content PubMed PubMed Citation Articles by Cohen, H. J. Articles by Bartolucci, A. A. Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma HJ Cohen, HR Silberman, K Tornyos and AA Bartolucci A randomized controlled trial was initiated in 1972 to compare two chemotherapeutic regimens [1-3-bis (2-chloroethyl) 1-nitrosourea (BCNU), cyclophosphamide, and prednisone versus melphalan and prednisone], to determine whether the two regimens are cross-resistant, and to evaluate the effectiveness of sodium fluoride, vitamin D, calcium gluconate, and fluoxymesterone in the promotion of bone healing. Initial responses (50%) and survival (36 mo median) for patients treated with the two chemotherapeutic regimens were the same. Patients on either regimen who failed to respond after 6 mo had a very low response rate to the alternative regimen (approximately 10%). Initially responding patients were randomly assigned to either an active drug regimen (sodium fluoride, vitamin D, calcium gluconate, fluoxymesterone) or placebo tablets. There was no significant difference in the low percentage of patients demonstrating bone improvement. Thus, the BCNU, cyclophosphamide, prednisone regimen is as effective as melphalan and prednisone. Fluoride, calcium, vitamin D, and androgenic steroids should not be routinely recommended in myeloma, as they seem to add little to effective chemotherapy and may contribute to morbidity. Volume 63, Issue 3, pp. 639-648, 03/01/1984 Copyright © 1984 by The American Society of Hematology CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. R. Berenson, A. Lichtenstein, L. Porter, M. A. Dimopoulos, R. Bordoni, S. George, A. Lipton, A. Keller, O. Ballester, M. J. Kovacs, et al. Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma N. Engl. J. Med., February 22, 1996; 334(8): 488 - 493. [Abstract] [Full Text] [PDF]

	Copyright © 1984 by American Society of Hematology         Online ISSN: 1528-0020